ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 2170
- Registration Number
- NCT03047395
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center /ID# 154000, Birmingham, Alabama, United States
🇺🇸Great Lakes Research Group - Bay City /ID# 153998, Bay City, Michigan, United States
🇺🇸Oregon Medical Research Center /ID# 154003, Portland, Oregon, United States
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 29
- Registration Number
- NCT03035279
- Locations
- 🇺🇸
University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States
🇺🇸Mayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
- Conditions
- Small Cell Lung Cancer
- Interventions
- Drug: Placebo for rovalpituzumab tesirine
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 748
- Registration Number
- NCT03033511
- Locations
- 🇺🇸
Parkland Health and Hosp Syste /ID# 170933, Dallas, Texas, United States
🇺🇸LA Hem-Oncology Med Group /ID# 156717, Los Angeles, California, United States
🇺🇸Thomas Jefferson University /ID# 156719, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 29
- Registration Number
- NCT03033498
- Locations
- 🇺🇸
Glendale Adventist Medical Ctr /ID# 166512, Glendale, California, United States
🇺🇸Acpru /Id# 154976, Grayslake, Illinois, United States
🇺🇸Parexel Baltimore /ID# 169255, Baltimore, Maryland, United States
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 42
- Registration Number
- NCT03026166
- Locations
- 🇺🇸
University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States
🇺🇸University of Chicago /ID# 161006, Chicago, Illinois, United States
🇪🇸Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT03022045
- Locations
- 🇯🇵
Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan
🇯🇵Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
🇯🇵Tokyo Medical University Hosp, Shinjuku-ku, Tokyo, Japan
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
- Conditions
- Crohn's Disease
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 62
- Registration Number
- NCT03017014
- Locations
- 🇫🇷
CHU Toulouse /ID# 153251, Toulouse CEDEX 3, Occitanie, France
🇫🇷CHU Bordeaux-Hopital Pellegrin /ID# 154620, Bordeaux, France
🇫🇷Chu de Bordeaux Hopital /Id# 157926, Bordeaux, France
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 950
- Registration Number
- NCT03006068
- Locations
- 🇭🇺
Meditres Kft. /ID# 151597, Kecskemet, Bacs-Kiskun, Hungary
🇯🇵Ieda Hospital /ID# 157782, Toyota-shi, Aichi, Japan
🇯🇵Sameshima Hospital /ID# 206673, Kagoshima-shi, Kagoshima, Japan
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
- Conditions
- Chronic Hepatitis C Virus (HCV)
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT03002818
- Locations
- 🇨🇭
Inselspital, Universitaetsklin, Bern, Switzerland
🇨🇭Hopital Neuchatelois, Neuchatel, Switzerland
🇨🇭Universitaetsspital Zuerich, Zurich, Switzerland
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000257
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, United States
🇺🇸The University of Chicago Medical Center /ID# 157375, Chicago, Illinois, United States
🇺🇸Virginia Cancer Specialists - Fairfax /ID# 157377, Fairfax, Virginia, United States